Clinical-stage Arcellx raised $123.8 million from its IPO, which the company will use to advance to a pivotal test for its lead program, a CAR T-cell therapy for multiple myeloma. Though Arcellx trails its large pharmaceutical rivals, the biotech contends its technology produces cell therapies with key advantages.
We are extending our INVEST 2022 Pitch Perfect deadline to Feb 11, 11:59 p.m. ET to allow interested startups to apply to the 4 tracks - PharmaTech, Diagnostics 2.0, Care Coordination and Value-Based Care, and Remote Patient Monitoring and Smart Devices. Slots are going fast so we encourage all startups - particularly those interested to apply in the PharmaTech and Diagnostics tracks to apply immediately. Selected startups will get to pitch LIVE on stage in front of VC judges. Here's the agenda for the INVEST conference.
Galvani Bioelectronics, a joint venture between Verily and GSK, recently announced the first successful implantation of a neurostimulator that uses splenic nerve stimulation as an experimental therapy for rheumatoid arthritis patients.
Validation Institute confirms study findings that Hello Heart 's AI-driven, smartphone-based solution saves employers an average of $1,865 per year for each participant who used Hello Heart by reducing trips to the ER, emergency surgeries, and imaging diagnostics.
By Michael Schroeder Sunday, February 6, 2022 9:00 AM
The report, released Monday, predicts 10 top growth opportunities in the industry and suggests that, with the healthcare consumerism boom, global revenues will hit $2.7 trillion by 2025.
No comments